Tryptase

The zones above describe one number in isolation, but tryptase rarely answers a question with one number. The real test is usually a comparison, and that is where the timing and the baseline come in.

The single most useful thing to understand about this marker is that you are not measuring a level so much as catching a moment. After a mast-cell storm, tryptase climbs fast and peaks within an hour or two, then drifts back down over the following day. Draw the blood inside that window and the footprints are sharp. Draw it the next morning, after the patient has been moved, settled, and observed overnight, and you are reading smooth snow: the prints have melted, and the number looks ordinary.

This is exactly why the NICE guideline frames the acute sample as best taken within about two hours of symptom onset and not beyond four. The window is partly biology and partly logistics: past four hours the level has often started to fall, and the patient may have moved on from where the sample would have been drawn, so the chance is simply missed.

The practical consequence trips up a lot of people. A reaction that looked and behaved like anaphylaxis, followed by a tryptase drawn too late and reported as normal, does not mean the reaction was not real. Anaphylaxis is diagnosed clinically, from what happened to the body; MedlinePlus describes it as a serious allergic reaction that can begin very quickly and turn life-threatening. The blood test supports that picture when the timing cooperates, and cannot overrule it when the timing does not.

A raised tryptase has two very different stories behind it, and separating them is most of the work.

The way clinicians tell an acute spike from a raised baseline is to take two samples and compare them, and there is a formula for it. The consensus rule, summarized in the mast-cell activation literature, holds that an acute tryptase counts as a meaningful rise only if it exceeds 1.2 times the person's baseline plus 2 ng/mL, shorthanded as the 20% + 2 rule. Everyone starts from a different resting level, so an absolute number lies; the rise above your own floor is the signal. The event draw and the baseline draw are two halves of one measurement, not two tests.

When the baseline itself stays high across calm-day draws, the question shifts from a single reaction to a steady-state cause, and the two candidates sit at opposite ends of the rarity scale: hereditary alpha-tryptasemia, common and usually harmless, versus systemic mastocytosis, uncommon and worth catching. Genetic testing and a bone-marrow assessment are how specialists separate them; the tryptase number only opens the door.

Low tryptase is the quiet end of the scale and rarely the point of the test. A value near the bottom of the assay's range usually just means little mast-cell enzyme was circulating at the moment of the draw. Because the test is built to catch increases over a personal baseline, a low or low-normal reading carries little of the weight a high one does.

Tryptase answers a narrow question well, but does not stand in for the rest of the allergy picture. IgE sits upstream of the same reaction, the antibody that recognizes an allergen and primes the mast cell to fire, so the two are often read together on an allergy panel as the trigger and the consequence. The cell counts add texture from the other direction: eosinophils swell in allergic disease, and basophils carry histamine alongside mast cells, both shifting on the allergic side of the immune system. When the question is whether general inflammation is muddying things, CRP is the usual reference point.

Because the most informative tryptase reading is a comparison, this is a marker where the trajectory matters as much as the point: an acute value means something only against a baseline, and a baseline means something only watched across more than one calm day. Since a draw taken too late can read normal after a textbook reaction, our guide to how much a result can be trusted explains why timing decides what this number is worth.